From the desk of Steve DeWitte, co-founder, CAP

MIT Research

I’m very excited to travel to Cambridge with Karl Hespeler and Kelly Kearney on July 10 for a follow-up meeting at MIT with renowned scientists Dr. Robert Langer and Dr. Ann Graybiel, to discuss our evolving partnership and Parkinson’s research.

Using InMotion as a Template

I’m proud to participate in the discussions to further the CAP wellness initiatives to possibly include a facility based on the successful template that  InMotion, in the Cleveland area, uses.  My friend Dr. Karen Jaffe is involved with this very successful group.

Working With Acadia Pharmaceuticals (and others)

NUPLAZID® is Acadia’s FDA approved drug for or the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.  I am working with Acadia to reinforce the positions of PWP’s related to actual outcomes and to factual data (in Acadia’s favor) vs. news reports that may have omitted key information. Read the MJFF note here.

As a Board member with CAP, I would like to acknowledge that we accept donations from companies, such as Acadia, in the true spirit of dedication to helping those PWP’s find new and better ways to manage their disease, and to live healthy lives. While CAP’s many offerings are in large part made possible by the generous support of good corporate citizens like Acadia, content and perspective are solely our own, and we always act in the best interests and on behalf of our members and PWP’s.

The medical information contained in this article is for general information purposes only. The Michael J. Fox Foundation for Parkinson's Research has a policy of refraining from advocating, endorsing or promoting any drug therapy, course of treatment, or specific company or institution. It is crucial that care and treatment decisions related to Parkinson's disease and any other medical condition be made in consultation with a physician or other qualified medical professional.

Van Andel Institute

I’m excited to once-again represent the cause of PWP’s, with an upcoming speaking engagement at the Van Andel Institute in Grand Rapids, Michigan.  The symposium I’m attending will be focused on the repurposing of existing drugs with the aim of assisting PWP’s.

Gordon Research Conference

I’m looking forward to speaking at a Gordon Research Conference later this month in Maine, where I’ll be speaking about “the things they don’t tell you in Post Doc School”.  Should be fun!

Clinical Trial Transportation Program

We recently completed a trip to Boston University, where our participants helped complete (fully enroll) a Clinical Trial testing the effects of exercise on PD.